Aarti Drugs Limited has submitted its quarterly compliance certificate to stock exchanges, fulfilling regulatory requirements under SEBI Regulation 74(5) for the quarter ended March 31, 2026. The pharmaceutical company filed the mandatory certificate on April 6, 2026, with both BSE and National Stock Exchange of India Limited.

Regulatory Compliance Certificate

The certificate was issued by MUFG Intime India Private Limited (formerly Link Intime India Private Limited), which serves as the registrar and transfer agent for Aarti Drugs Limited. The document confirms compliance with Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.

Certificate Confirmation

MUFG Intime India Private Limited confirmed that all securities received from depository participants for dematerialisation during the quarter were properly processed. The registrar verified that:

• Securities received for dematerialisation were confirmed or rejected to depositories within prescribed timelines
• All security certificates were mutilated and cancelled after due verification
• Depository names were substituted in the register of members as registered owners
• Securities comprised in certificates have been listed on stock exchanges where earlier issued securities are listed

Corporate Information

Aarti Drugs Limited operates as a manufacturer of bulk drugs and chemicals. The company's corporate office is located at Mahendra Industrial Estate, Sion (East), Mumbai, while its registered office is situated at MIDC Tarapur, Village Pamtermbhi, District Palghar, Thane.

The certificate was signed by Rushikesh Deole, Company Secretary and Compliance Officer, and Ashok Shetty, Sr. Vice President-Corporate Registry at MUFG Intime India Private Limited. This filing represents routine regulatory compliance, ensuring transparency in the company's dematerialisation processes and adherence to SEBI guidelines for depositories and participants.

Aarti Drugs Limited has received reaffirmation of its credit ratings from ICRA Limited for various banking facilities totaling Rs. 1,452.80 crore. The pharmaceutical company announced this development on March 24, 2026, in compliance with Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

Credit Rating Details

ICRA Limited has reaffirmed its ratings across multiple facility categories for Aarti Drugs Limited. The rating agency maintained its assessment of the company's creditworthiness across both long-term and short-term instruments.

Banking Partner Distribution

The rated facilities are distributed across multiple banking institutions, reflecting the company's diversified funding approach. For long-term facilities rated on the long-term scale, Kotak Mahindra Bank provides the term loan facility of Rs. 253.13 crore, while Union Bank of India handles the cash credit facility of Rs. 65.00 crore.

Short-term Working Capital Facilities

The short-term facilities totaling Rs. 1,085.00 crore are structured across fund-based and non-fund based categories:

Fund-based facilities (Rs. 535.00 crore):

• HDFC Bank Limited: Rs. 196.00 crore
• Axis Bank Limited: Rs. 145.00 crore
• State Bank of India: Rs. 75.00 crore
• DBS Bank Limited: Rs. 43.00 crore
• Kotak Mahindra Bank Limited: Rs. 40.00 crore
• Standard Chartered Bank: Rs. 35.00 crore
• IDBI Bank Limited: Rs. 1.00 crore

Non-fund based facilities (Rs. 550.00 crore):

• Kotak Mahindra Bank Limited: Rs. 140.00 crore
• HDFC Bank Limited: Rs. 104.00 crore
• HSBC Limited: Rs. 100.00 crore
• Axis Bank Limited: Rs. 80.00 crore
• Standard Chartered Bank: Rs. 65.00 crore
• IDBI Bank Limited: Rs. 44.00 crore
• DBS Bank Limited: Rs. 12.00 crore
• Union Bank of India: Rs. 5.00 crore

Rating Significance

The [ICRA] AA- (Stable) rating indicates high credit quality with adequate degree of safety regarding timely servicing of financial obligations. The A1+ rating for short-term instruments reflects the highest credit quality and indicates very strong degree of safety regarding timely payment of financial obligations. The reaffirmation of these ratings demonstrates ICRA's continued confidence in Aarti Drugs Limited's financial strength and debt servicing capabilities.

ICRA has indicated that the ratings will become due for surveillance within one year from March 24, 2026. The rating agency reserves the right to review and revise the ratings based on new information or changing circumstances that could impact the company's creditworthiness.